Evogene (NASDAQ:EVGN) Issues Earnings Results, Misses Estimates By $0.33 EPS

Evogene (NASDAQ:EVGN) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.33), FiscalAI reports. The company had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.35 million. Evogene had a negative return on equity of 121.44% and a negative net margin of 214.57%.

Evogene Stock Up 4.4%

Shares of Evogene stock opened at $0.73 on Wednesday. The firm has a market cap of $6.37 million, a price-to-earnings ratio of -0.62 and a beta of 1.39. The business has a fifty day simple moving average of $0.80 and a 200-day simple moving average of $0.96. Evogene has a fifty-two week low of $0.70 and a fifty-two week high of $2.42.

Institutional Trading of Evogene

Several institutional investors have recently modified their holdings of EVGN. Citadel Advisors LLC lifted its holdings in shares of Evogene by 169.4% in the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 36,206 shares during the period. XTX Topco Ltd purchased a new stake in shares of Evogene during the fourth quarter valued at $25,000. Finally, Jane Street Group LLC lifted its holdings in shares of Evogene by 58.0% during the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 12,387 shares during the last quarter. Institutional investors and hedge funds own 10.40% of the company’s stock.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.